Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > 64.5 million traded at 3.5 cents average

<< Previous

Bullboard Posts

Next >>

Comment by Walterthedogon Dec 29, 2020 5:47pm

206 Views

Post# 32193908

RE:RE:RE:64.5 million traded at 3.5 cents average

I think people are putting too much emphasis on the RS. Any serious investor was buying today based on their perception of where the market cap is headed and the RS doesn't effect the real value. Lots of penny flippers were likely chasing volume but I'd bet many were serious investors interested in long term gains

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?